To read our full disclaimer, click here.
There is an exclusive offer at the bottom for anyone who wants the full theses behind these names.
Ten of the nineteen companies I cover had news this week. Two sets of quarterly and full-year numbers, a pivotal trial readout followed the same day by a $50 million raise, a completed Phase 3 enrolment, a refinancing, a debt buyback and a reverse split ahead of a Nasdaq uplisting.
Everything below is what the companies announced, with the figures as reported. My own read on what it means for each thesis lives in the research portal.
PMV Pharmaceuticals (PMVP)
The busiest week of any name on the list, and the two events are connected.
On 31 August PMV reported updated interim data from the pivotal Phase 2 portion of PYNNACLE, covering 76 platinum-resistant and refractory ovarian cancer patients. Overall response rate was 46%, or 35 of 76 patients, made up of 4 confirmed complete responses, 29 confirmed partial responses and 2 unconfirmed. Median time to response was 1.3 months and median duration of response was 10.0 months. Treatment-related adverse events were mostly Grade 1 to 2, with a 5% discontinuation rate.
The company also said it has FDA feedback supporting an NDA submission for accelerated approval of rezatapopt in TP53 Y220C mutant platinum-resistant and refractory ovarian cancer, targeted for Q1 2027. Primary analysis data from all Phase 2 cohorts is planned for a medical conference in Q4 2026.
Later the same day PMV announced a proposed public offering, then priced it: 22,055,000 shares plus pre-funded warrants over 19,900,000 shares, each with accompanying warrants covering 41,955,000 shares in aggregate, at $1.21 per share and accompanying warrant. The warrants carry a $1.21 exercise price, subject to adjustment following a specified regulatory milestone, and a five-year term. Gross proceeds were approximately $50.8 million before costs, described as oversubscribed, with TD Cowen sole book-running manager and closing expected around 2 September.
Pro-Dex (PDEX)
Fiscal 2026 fourth quarter and full-year results landed on 3 September.
Q4 net sales rose 17% year on year to $20.4 million, with net income of $2.9 million, or $0.87 per diluted share. Gross margin came in at 35%, against 20% in the same quarter last year.
For the full year, net sales rose 16% to $77.5 million and net income was $13.7 million, or $4.12 per diluted share, at a 31% gross margin against 29%. Growth came mainly from the largest customer’s next generation orthopedic handpiece, partly offset by a $6.0 million reduction in repair revenue from that same customer. The February 2026 acquisition of Advanced Precision Machining added $718,000 of revenue across the year.
Hydreight Technologies (NURS.V)
Record Q2 numbers on 31 August. Revenue rose 421% year on year to $28.0 million from $5.4 million, and 12.5% sequentially. Gross profit rose 182% to $5.4 million. Net income was $2.5 million against $0.05 million, and adjusted EBITDA $3.2 million against $0.2 million.
The VSDHOne virtual healthcare and direct-to-consumer platform produced $22.8 million of that quarterly revenue, up from $0.7 million a year earlier. Pharmacy sales reached $26.2 million from $4.5 million.
First-half revenue was $53.0 million, up 434%, with net income of $5.1 million and adjusted EBITDA of about $6.5 million. Cash stood at $20.0 million and working capital at $35.0 million at 30 June, after $8.7 million of operating cash used in the half. Management reaffirmed full-year guidance of approximately $150 million.
Covalon Technologies (COV.V)
Fiscal third quarter results on 27 August. Revenue rose 20% year on year to $10.0 million, gross margin expanded to 67.2% from 46.5%, and net income was $2.8 million against $0.06 million a year earlier, or $0.10 diluted. Adjusted EBITDA more than tripled to $3.0 million from $0.9 million.
Underneath that, Contamination Protection revenue grew 68% year on year and 34% sequentially, and the US Vascular Access channel grew 51%, which the company put at roughly ten times the underlying market growth rate. Cash closed the quarter at $19.4 million with no bank debt, up $2.8 million in three months.
Ion Beam Applications (IBAB)
Half year results on 27 August. Net sales rose 6% to €323.7 million, gross margin improved to 33.7% from 29.5%, and adjusted EBIT rose to €17.6 million from €10.6 million, with the Proton Therapy turnaround contributing €12.3 million of that. The net result swung to €9.3 million from a €2.6 million loss, giving EPS of €0.32. Full-year adjusted EBIT guidance of at least €32 million was reiterated.
Equipment order intake grew 64% to €176 million, with IBA Clinical more than doubling to €148 million on five proton therapy rooms sold. Backlog held stable at €1.6 billion. Net debt rose to €81 million at 30 June from €57 million at 31 March, mainly on working capital movements and temporary ERP-related invoicing delays, with the net financial position expected to improve over 2027.
Then on 2 September IBA joined PFAROS, a European research initiative funded under the Innovative Health Initiative Joint Undertaking bringing together 91 partners to reduce PFAS emissions across the life cycle of medical products. IBA and Bayer co-lead the work on end-of-life and waste management technologies, with IBA assessing its electron beam and Rhodotron technology for PFAS destruction in hospital and pharmaceutical wastewater. No financial terms were disclosed.
Emergent BioSolutions (EBS)
Four releases, two of them commercial.
On 31 August Emergent was awarded a Government of Canada standing offer for NARCAN Nasal Spray 4 mg, running from 1 October 2026 to 30 September 2029 with an option to extend by two further years. It allows federal departments, agencies, Crown corporations, provinces, territories and other designated public sector bodies to purchase the product, and follows an existing five-year standing offer expiring this September. No value was disclosed.
On 1 September came a BARDA contract modification worth approximately $24 million to supply CYFENDUS for anthrax preparedness under federal contract HHSO100201600030C. The release also referenced an earlier 2026 delivery order worth up to $21.5 million for BioThrax. Delivery timing was not disclosed.
On 3 September Emergent completed the repurchase of $75 million aggregate principal of its 3.875% Senior Unsecured Notes due 2028, for approximately $68 million in cash, an average of 90.6% of face value. That leaves approximately $364.7 million outstanding. The buyback was funded from cash, with $50 million still available under the asset-based revolving facility, and management said it will watch market conditions for refinancing the rest ahead of the August 2028 maturity.
The fourth was an International Overdose Awareness Day release with no commercial terms.
Verrica Pharmaceuticals (VRCA)
On 27 August Verrica completed enrolment in COVE-2, the first of two pivotal Phase 3 trials of YCANTH in common warts. The study is double-blind, randomised and vehicle-controlled, dosing once every 21 days for up to four applications in patients aged 2 and older.
A pre-specified interim analysis by an independent statistician confirmed no additional patients are needed for adequate statistical power. Topline COVE-2 data is expected in Q1 2027, with the rest of the programme, including COVE-3 which is more than 50% enrolled across US and Japanese sites, anticipated by mid-2027. Common warts affect approximately 22 million US patients and there are no FDA-approved prescription therapies.
CareRx Corporation (CRRX)
A new senior secured credit agreement with National Bank of Canada, announced 27 August. It comprises a $20 million revolving operating facility, a $40 million term loan and a $10 million acquisition and capex facility, giving $70 million available at closing and expandable by up to a further $20 million.
The full term loan was drawn at closing to repay and discharge the existing facility, which the new agreement replaces entirely. Management expects cost savings against the prior facility and framed it as lowering the overall cost of capital while adding dedicated capacity to invest.
Interpace Biosciences (IDXG)
A 1-for-5 reverse stock split took effect on 27 August, cutting shares outstanding from approximately 27.7 million to approximately 5.5 million, with fractional shares rounded up and proportional adjustments to options, RSUs and equity plans.
Stockholders approved it on 20 August. The purpose is to meet the Nasdaq Capital Market minimum bid price requirement ahead of a proposed uplisting from OTCID, where the stock trades temporarily as IDXGD for 20 trading days before reverting to IDXG. Other listing requirements still apply, including a $15 million market value of unrestricted publicly held shares, and the company cautioned there is no guarantee the uplisting completes.
Also this week
Eton Pharmaceuticals (ETON) confirmed it will present at the 2026 Wells Fargo Healthcare Conference, and Hydreight gave notice of its results date ahead of the numbers above.
Quiet this week: Fennec Pharmaceuticals, Innovotech, Journey Medical, NeuPath Health, Precipio, Sanara MedTech, SANUWAVE Health, Vaso Corporation and Viemed Healthcare.
Where the thesis behind each of these lives
A week like this is exactly the problem with following microcaps.
Ten companies moved, some of it genuinely mattering and some of it noise, and the release itself never tells you which is which. A 46% response rate means nothing until you know what the trial had to beat. A $24 million contract modification reads as good news until you check what the thesis was actually waiting for.
Next week I am opening the Healthcare Stock Ideas Research Portal to paid subscribers.
It is the live archive of everything I cover here.
One page per company, holding the current thesis rather than a pile of old posts: what the business does, why it is an idea, what I think the market is missing, the risks, and what I am watching for next.
Searchable and filterable by sector, geography and conviction.
Each page carries a price chart at the top and an auto-updating filings timeline underneath, so every announcement in this roundup is already sitting on the relevant company’s page in date order.
It is not a screener and it is not a list of tips. It is the working file I keep for myself, opened up.
Which also means roundups like this one get more useful from next week.
Every company named above will have a page you can click straight through to, so instead of reading that Covalon’s gross margin went to 67.2% and wondering whether that is the thesis working, you can go and read what the thesis said should happen.
To mark the launch, I am running 25% off the annual plan. It applies to your first year and it is available for a limited time only.
Paid subscribers get every deep dive, the full archive, and from next week the research portal itself.
Thanks for reading,
Nico
Disclaimer: The content provided in this newsletter is for informational purposes only and does not constitute financial, investment, or other professional advice. The opinions expressed here are those of the author and do not necessarily reflect the views of Healthcare Stock Ideas. Investing involves risk, including the possible loss of principal. Past performance is not indicative of future results. The author may or may not hold positions in the stocks or other financial instruments mentioned. Always do your own research or consult with a qualified financial advisor before making any investment decisions. To read our full disclaimer, click here.
Where can we see a detailed tracker? It's very very hard to navigate your portfolio as I could not find any solution
Has this been released? Without Model Portfolio and conviction tracker like with MI, it is very difficult to put ideas into practice